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Abstract
Background: Considering neoadjuvant chemotherapy (NAC) prior to surgery could shrink and reduce the primary
tumor and distant micro-metastases to reduce the high relapses rates, NAC has been an accepted therapeutic
management for patients with non-small cell lung cancer (NSCLC). CMTM1_v17 is highly expressed in human testis
tissues and solid tumor tissues but relatively low expression was obtained in the corresponding normal tissues. This
study aims to investigate the significance of CMTM1_v17 in NSCLC and its association with platinum-based NAC
efficacy.
Methods: 31 pairs of tumor tissues before and after NAC and 78 resected tumor tissues after NAC were utilized for
immunohistochemistry (IHC) staining of CMTM1_v17 protein. The correlation between CMTM1_v17 expression and
chemotherapy efficacy was analyzed. The prognostic value of CMTM1_v17 index for disease-free survival (DFS) and
overall survival (OS) was analyzed using Kaplan-Meier survival and multivariable Cox regression.
Results: CMTM1_v17 expression was related to treatment effect and outcome in tumor tissues after NAC not
before NAC from 31 cases of NSCLC. We identified that high CMTM1_v17 expression was associated with low
objective remission rate (ORR) (P = 0.008) and poor prognosis (the median OS: 35.1 months vs 65.6 months, P = 0.
0045; the median DFS: 17.27 months vs 35.54 months, P = 0.0207) in the 31 patients. Next, we detected CMTM1_
v17 expression to confirm correlation between this protein status and clinical characteristics in 78 NSCLC patients
with NAC treatment. The upregulation of CMTM1_v17 had a higher SD rate (P = 0.007) and worse outcome (the
median OS: 41.0 months vs 80.6 months, P = 0.0028; the median DFS: 33.4 vs 64.8 months, P = 0.0032). COX
multivariate analysis indicated that CMTM1_v17 is an independent prognostic risk factor on patients who have
received NAC (OS: HR = 3.642, P = 0.002; DFS:HR = 3.094, P = 0.002).
Conclusions: CMTM1_v17 expression is significantly associated with chemoresistance and poor prognosis of the
early stage NSCLC patients who have received NAC.
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Background
Lung cancer remains the leading cause of cancer-related
mortality for both men and women in China [1]. Non-
small cell lung cancer (NSCLC) is the most commonly
diagnosed lung cancers, accounting for up to 80% of all
histological subtype of lung cancer [2]. Patients with
NSCLC in stage IIB/IIIA generally have unfavorable
prognosis [3]. The neoadjuvant chemotherapy (NAC)
prior to surgery has been reported to shrink and reduce
the primary tumor and distant micro-metastases,
thereby reducing the high relapses rates [4]. In our pre-
vious study, platinum-based NAC was demonstrated to
significantly increase disease-free survival (DFS) time for
patients with stage IIB-IIIA central disease [5]. Factors
such as good pathological response and shrinkage of
mediastinal nodal have been reported to be related to
NAC efficacy in several randomized trials [6–8], but
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biological molecular markers’ variation for the patients
with NAC have not been fully investigated.
The CMTM1 gene is a member of the chemokine-like
factor superfamily (CKLFSF). CMTM1_v17 is one of the
23 variants of CMTM1. The protein is composed by 149
amino acids [9]. In humans, CMTM1_v17 apparently
exhibits a tissue-specific expression. High level of
CMTM1_v17 is expressed in testicles and prostate tis-
sues but low or undetectable level is found in many nor-
mal tissues [10]. Previous investigation demonstrated
that CMTM1_v17 expressed in various types of solid
tumors (breast cancer, kidney cancer, lung cancer, liver can-
cer, and ovarian cancer) and could promote the prolifera-
tion and lead to partial resistance to tumor necrosis factor-
α (TNF-α) induced apoptosis via activation of NF-κB
signaling pathway in breast cancer [11]. However, little is
known about the significance of CMTM1_v17 in NSCLC
and its association with platinum-based NAC efficacy.
In the present study, we investigated the expression of
CMTM1_v17 in tumor tissues of NSCLC patients before
and after NAC using IHC to determine whether the
expression of CMTM1_v17 could have the predictive
value for the rational application of NAC and prognostic
value in NSCLC patients.
Methods
Patients
A total of 78 NSCLC patients, who had been treated with
NAC and surgery from July 2006 to April 2012, were
enrolled in our study. The median age at diagnosis was
56 years (range, 38 to 75 years). Patients were selected for
our study based on the following features: (1) all patients
had been diagnosed with NSCLC by pathological diagno-
sis; (2) presence of central disease with T2bN1, T3 or T4
N0, or locally advanced disease with T1 to T3 N2; (3) pa-
tients had received at least 2 cycles of platinum-based
chemotherapy followed by surgery; (4) had no advanced
disease such as N3 or M1; (5) had not received radiother-
apy; (6) clinical variables were recorded in detail including
gender, age, histology, smoking, disease location, chemo-
therapy regimen, clinical response, TNM stage, disease re-
currence, and survival. Matched biopsy and surgical
resection samples were collected in 31 of 78 NSCLC pa-
tients before and after neoadjuvant treatment.
Patients’ clinical and pathological features were derived
from the clinical database established in 2000. Pathologic
staging of lung cancer was reviewed and classified accord-
ing to the 2009 International Union Against Cancer–
American Joint Committee on Cancer–TNM system
(version 7) [12]. Histologic subtypes were based on the
World Health Organization (WHO) criteria [13].
The study was conducted with the approval of the
Institutional Ethic Committee at Peking University Can-
cer Hospital. Lung tumor samples were analyzed with
the agreement of the patients who have signed informed
consent.
IHC and quantification of CMTM1_v17 positive tumor cells
Formalin-fixed and paraffin-embedded primary lung
cancer samples were acquired from the Department of
Pathology, Peking University, under approval from the
Ethical Committee. For CMTM1_v17 staining, sections
(4 um) were routinely processed and stained using
mouse anti-CMTM1_v17 (1:800 dilution; acquired from
Wang Lu; School of Basic Medical Sciences, Health Sci-
ence Center, Peking University, Department of Immun-
ology) polyclonal antibody followed by incubation with
HRP-conjugated goat anti-mouse secondary antibody
(Sigma-Aldrich, Poole, Dorset, UK). For determination of
immunoreactivity for CMTM1_v17, cytosolic staining of
yellowish or brownish granules was graded as follows:
(a) for background staining; (b) for negative staining;
(c) for moderate staining, and (d) for strong staining. In
addition, positive staining areas in the entire tissue
section were graded as follows: 0 for <5%; 1 for 5–25%;
2 for 26–50%, and 3 >50%. When combining these two
parameters, 0–1 and >1 were considered CMTM1_v17
low expression and CMTM1_v17 high expression,
respectively.
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Table 2 Patients’ characteristics and levels of CMTM1_v17 expression pre- and post-NAC (n = 31)
Variable Pre-NAC Post-NAC
CMTM1_v17 expression no. (%) P value CMTM1_v17 expression no. (%) P value
High Low High Low
Age 0.200 0.552
≤ 55 7(43.8) 9(56.3) 7(43.8) 9(56.2)
> 55 10(66.7) 5(33.3) 5(33.3) 10(66.7)
Gender 0.763 0.791
Male 10(40.0) 15(60.0) 14(56.0) 11(44.0)
Female 2(33.3) 4(66.7) 3(50.0) 3(50.0)
Smoking history 0.935 0.75
Non-smoker 3(37.5) 5(62.5) 4(50.0) 4(50.0)
Smoker 9(39.1) 14(60.9) 13(56.5) 10(43.5)
Histology 0.332 0.981
Adenocarcinoma 3(27.3) 8(72.7) 6(54.5) 5(45.5)
Non-adenocarcinoma 9(45.0) 11(55.0) 11(55.0) 9(45.0)
Histologic grading 0.379 0.576
Poorly 5(31.3) 11(68.7) 8(50.0) 8(50.0)
Moderate and well 7(46.7) 8(53.3) 9(60.0) 6(40.0)
Venous invasion 0.355 0.75
Negative 10(43.5) 13(56.5) 13(56.5) 10(43.5)
Positive 2(25.0) 6(75.0) 4(50.0) 4(50.0)
Pathological stage 0.756 0.092
I/II 7(41.2) 10(58.8) 7(41.2) 10(58.8)
III 5(35.7) 9(64.3) 10(71.4) 4(28.6)
P value was calculated using Pearson’s χ2 test
NAC neoadjuvant chemotherapy
Fig. 1 Immunohistochemical staining for CMTM1_v17. a, b The low expression of CMTM1_v17 in non-small cell lung cancer (NSCLC) primary
tumor; (c, d) The high expression of CMTM1_v17 in NSCLC primary tumor; the magnification was ×200
Si et al. World Journal of Surgical Oncology  (2017) 15:34 Page 3 of 10
Statistical analysis
All statistical analyses were performed with the Statistical
Package for Social Sciences software version 17.0
(SPSS17.0). The correlation between CMTM1-v17 expres-
sion and clinicopathologic variables was assessed using
Pearson’s chi-squared test or Fisher’s exact test. Disease-
free survival (DFS) was defined as the time from surgery
to tumor recurrence, death or the date of the last follow-
up. The survival rates were estimated using the Kaplan-
Meier method, and the differences in survival between the
subgroups were compared using the log-rank test. A
multivariate analysis was conducted to study the prognos-
tic value of CMTM1_V17 using the Cox proportional-
hazard model. A two sided P value of less than 0.05 was
considered to be statistically significant at all situations.
Results
CMTM1_v17 variation in the NSCLC cancers before and
after NAC
Thirty-one NSCLC patients were recruited into the
study from July 2006 to April 2012. Patients’ sociodemo-
graphic, pathologic, and clinical characteristics were
listed in Table 1. Tumor core biopsies were successfully
obtained in 31 cases of these patients before NAC.
Figure 1 illustrated representative CMTM1_v17 IHC
staining. Lung cancer tissues showed strong and diffuse
cytoplasmic staining of CMTM1_v17. In 31 NSCLC
patients, the correlation of CMTM1_v17 expression in
tumor tissues pre- and post-NAC according to various
prognostic groups was shown in Table 2. There was no
significant correlation of CMTM1_v17 expression with
any other parameters, such as patients’ age, gender, smok-
ing history, histology, pathological stage, though there
were more cases with CMTM1_v17 high expression after
NAC in pathological stage III (71.4%) compared to patho-
logical stage I/II (41.2%).
To assess the clinical significance of CMTM1_v17
expression in 31 NSCLC, we analyzed the relationship
between CMTM1_v17 expression and NAC efficacy.
The results showed that the expression of CMTM1_v17
in tumor tissues after NAC strongly correlated with NAC
efficacy, with partial response (PR) rates of only 25.0% in
CMTM1_v17 high expression tumors compared to 73.7%
in CMTM1_v17 low expression tumors (P = 0.008, Fig. 2a).
However, there was no significant association between
CMTM1_v17 expression in tumor tissues before NAC
and chemotherapy response (P = 0.788, Fig. 2b).
Moreover, we identified that high expression level of
CMTM1_v17 in tumor tissues after NAC strongly was
correlated with poor survival (DFS: P = 0.0207, Fig. 2c; OS:
P = 0.0045, Fig. 2d). But the expression of CMTM1_v17 in
tumor tissues before NAC was not associated with DFS
Table 3 Univariate analysis of clinicopathological factors for OS and DFS in patients with NSCLC (n = 31)
Variables OS DFS
HR 95%CI P value HR 95%CI P value
Age
≤ 55 vs > 55 0.3624 0.1117–1.175 0.0908 0.3255 0.1182–0.8964 0.0299
Gender
Male vs female 0.7042 0.1642–3.020 0.6368 0.4944 0.1269–1.927 0.3101
Smoking
Non-smoker vs smoker 1.698 0.4399–6.552 0.4423 1.672 0.5113–5.469 0.395
Histology




2.005 0.6213–6.473 0.2445 2.079 0.7724–5.595 0.1474
Venous Invasion
Negative vs positive 1.352 0.3956–4.619 0.6306 1.237 0.4191–3.653 0.6999
Pathological stage
I/II vs III 0.3045 0.09458–0.9802 0.0462 0.3044 0.1083–0.8553 0.024
Pre-NAC CMTM1_v17
Low vs high 0.3753 0.09230-1.526 0.1708 1.002 0.3533–2.842 0.9971
Post-NAC CMTM1_v17
High vs low 0.1587 0.04462–0.5647 0.0045 0.3099 0.1149–0.8360 0.0207
P value was calculated using a two-sided log-rank test.
AD adenocarcinoma, NAC neoadjuvant chemotherapy, HR hazard ratio (log-rank), CI confidence interval.
Bold values are significant (p < 0.05)
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Fig. 2 Chemotherapy efficacy and prognosis analysis according to CMTM1_v17 expression pre- and post-chemotherapy in 31 patients. a At the
end of NAC, patients with low expression of CMTM1_v17 were sensitive to chemotherapy, with high PR rates compared to those who were
CMTM1_v17 high expression (P = 0.008). b Before NAC, there was no significant difference in chemotherapy efficacy in CMTM1_v17 high vs
CMTM1_v17 low groups (P = 0.788). These Kaplan-Meier curves illustrate the prognostic significance of CMTM1_v17 pre- and post-NAC in 31
NSCLC patients. c, d At the end of NAC, patients with low expression of CMTM1_v17 had much better prognosis compared to those who were
CMTM1_v17 high expression. e, f Before NAC, there was no significant difference in DFS and OS in CMTM1_v17 high vs CMTM1_v17 low groups.
OS, overall survival; DFS, disease-free survival; NAC: neoadjuvant chemotherapy
Table 4 Multivariable analysis of OS and DFS in patients received NAC (n = 31)
Variable OS DFS
HR 95%CI p value HR 95%CI p value
Post-NAC CMTM1_v17
Low vs high 0.074 0.008–0.670 0.021 0.455 0.136–1.517 0.12
Pathological stage
I/II vs III 0.295 0.082–1.049 0.059 0.319 0.107–0.951 0.04
Age
≤ 55 vs > 55 0.291 0.923–0.915 0.035
P value was calculated using a two-sided log-rank test.
OS overall survival, DFS disease-free survival, HR hazard ratio (log-rank), CI confidence interval.
Bold values are significant (P < 0.05)
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(P = 0.9971, Fig. 2e) and OS (P = 0.1708, Fig. 2f). That is
to say, high expression level of CMTM1_v17 in tumor
tissues after NAC was associated with chemoresistance
and poor prognosis, while CMTM1_v17 expression in
tumor tissues before NAC was not correlated with chemo-
therapy response and survival.
Then univariate and multivariate analyses were per-
formed to identify clinicopathological factors influencing
the OS and 5-year DFS according to the Cox propor-
tional hazard model, and the log-rank test was used to
compare the two groups. Among the clinical factors, high
expression level of CMTM1_v17 post-NAC was signifi-
cantly correlated with a shorter OS (P = 0.021, HR = 0.074).
Older age (>55 years) and pathological stage III were
significantly correlated with shorter DFS (Tables 3 and 4).
CMTM1_v17 expression level was related to
chemoresistance and prognosis after NAC
Due to the small sample size of our study, COX multi-
variate analysis suggested that CMTM1_v17 was not
associated with DFS in 31 NSCLC patients. Therefore,
we added 47 NSCLC patients with NAC prior to surgery
during that same period to our study. There was no
significant difference between age, gender, smoking
history, pathological stage, differentiation, among those
patients (Table 5). Then, the relationship between
CMTM1_v17 expression and chemoresistance and survival
were analyzed in 78 patients who have received NAC.
Among 78 patients with NAC, 4 patients could not be
evaluated the response to NAC because of the absence
of clinical pathological features. The correlation of
CMTM1_v17 expression and chemotherapy efficacy was
analyzed on the remaining 74 patients with NAC treat-
ment. The results also supported above findings, as sum-
marized in Fig. 3. A high CMTM1_v17 expression level in
the lung cancer cells was significantly correlated with che-
moresistance (P = 0.007, Fig. 3a) and inferior DFS (P =
0.0032, Fig. 3b) and OS (P = 0.0026, Fig. 3c), compared
with patients with a low CMTM1_v17 expression level.
The association of CMTM1_v17 expression with patient
clinicopathological parameters was shown in Table 6.
COX univariate and multivariate analysis suggested
that CMTM1_v17 is an independent prognostic risk
factor in 78 NSCLC patients who have received NAC
(OS: HR = 3.642, P = 0.002; DFS: HR = 3.094, P = 0.002,
Tables 7 and 8). Collectively, these results strongly
Table 5 Patient’s characteristic, overall and according to the time of enrollment
Variable Overall Original patients group Added patients group P value
no. (%) no. (%) no. (%)
Total 78(100%) 31(39.7%) 47(60.3%)
Age 0.246
≤ 55 32(41.1%) 16(50.0%) 16(50.0%)
> 55 46(58.9%) 15(32.6%) 31(67.4%)
Gender 0.793
Male 64(82.1%) 25(39.1%) 39(60.9%)
Female 14(17.8%) 6(42.9%) 8(57.1%)
Smoking history 0.978
Non-smoker 20(25.6%) 8(40.0%) 12(60.0%)
Smoker 58(74.4%) 23(39.7%) 35(60.3%)
Histology 0.661
Adenocarcinoma 30(38.5%) 11(36.7%) 19(63.3%)
Non-adenocarcinoma 48(61.5%) 20(41.7%) 28(58.3%)
Histologic grading 0.549
Poorly 37(47.4%) 16(43.2%) 21(56.8%)
Moderate and well 41(52.6%) 15(36.6%) 26(63.4%)
Venous invasion 0.347
Negative 62(79.5%) 23(37.1%) 39(62.9%)
Positive 16(20.5%) 8(50.0%) 8(50.0%)
Pathological stage 0.744
I/II 41(52.6%) 17(41.5%) 24(58.5%)
III 37(47.4%) 14(37.8%) 23(62.2%)
P value was calculated using Pearson’s χ2 test
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indicate that CMTM1_v17 expression is directly associ-
ated with chemotherapy efficacy and prognosis for
patients who have received NAC.
Discussion
The aim of this study was to investigate the significance
of CMTM1_v17 in NSCLC and its association with
platinum-based NAC efficacy. The expression status of
CMTM1_v17 in patients with NSCLC before and after
treatment with NAC was evaluated. We demonstrated
that a high expression of CMTM1_v17 confers chemore-
sistance and poor clinical outcome in patients who have
received NAC. To our knowledge, this is the first study
to demonstrate the correlation between CMTM1_v17
expression and chemotherapy efficacy and prognosis.
Cisplatin was approved by FDA for treating testicular
tumors and bladder cancers for the first time in 1978,
and gradually employed in the treatment of multiple
solid tumors. However, cisplatin has poor curative effect
for the NSCLC disease compared with response of this
drug on the other type of solid cancers. Cisplatin exerts
anticancer effects mainly via the generation of DNA le-
sions followed by the activation of the DNA damage
response and the induction of mitochondrial apoptosis
[14, 15]. Previous investigations have demonstrated that
TP53, BCL-2 family, caspase family, and MAPK family
often influence cisplatin sensitivity in tumor cells via cell
apoptosis [16–24].
The strong impact of CMTM1_v17 in promoting
tumor cell proliferation and lead to partial resistance to
Fig. 3 Chemotherapy efficacy and prognostic significance of
CMTM1_v17 expression in patients with NAC treatment. a PR rates
were higher in patients with CMTM1_v17 low expression than those
with CMTM1_v17 high expression. b, c Patients with low expression
of CMTM1_v17 had significantly better DFS and OS compared to
those with high expression of CMTM1_v17 after NAC. NAC
neoadjuvant chemotherapy; PR partial response; OS overall survival;
DFS disease-free survival
Table 6 Patients’ characteristics and levels of CMTM1_v17
expression in patients received NAC (n = 78)
Variable CMTM1_v17 expression no. (%) P value
High Low
Age 0.315
≤ 55 13(40.6) 19(59.4)



















P value was calculated using Pearson’s χ2 test.
NAC neoadjuvant chemotherapy
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TNF-α-induced apoptosis likely via activation of NF-κB
signaling pathway has been validated in breast cancer
[11]. Previous study revealed that TNF-α could increase
the sensitivity of cancer cells to cisplatin-induced cell
death by NF-κB signaling pathway [25]. Furthermore,
the activation of the NF-κB pathway has also been
reported to be associated with cisplatin resistance
[26].Therefore, we developed a hypothesis that the high
expression of CMTM1_v17 could promote chemoresis-
tance. When analyzing chemotherapy efficacy in the
correlation of the expression level of CMTM1_v17,
patients with low CMTM1_v17 expression in the tumor
tissues after NAC suggested higher PR rates than those
with high CMTM1_v17 expression, which were con-
firmed in 78 NSCLC patients who have received NAC.
However, the expression of CMTM1_v17 in the tumor
tissues before NAC was not a predictor of response to
chemotherapy. The above hypothesis was verified by the
results that CMTM1_v17 high expression was correlated
to chemoresistance in NSCLC patients treated with NAC.
Our results are significantly important from the opinion
that it could distinguish patients who are possibility to
benefit from adjuvant chemotherapy towards personalized
treatment.
Then the impact of CMTM1_v17 on prognosis was
analyzed. Patients with low CMTM1_v17 expression in
tumor tissues after NAC lived significantly longer than
those with high CMTM1_v17 expression, but there is no
association between CMTM1_v17 expression in tumor
tissues before NAC and survival. These results identified
that the expression level of CMTM1_v17 might be a
prognostic marker only in NSCLC patients who have
received NAC. These findings are similar to those of
Alamgeer et al. [27], who reported that chemotherapy
could affect the expression of ALDH1 in breast cancer,
and the expression of ALDH1 at baseline does not im-
pact the long-term prognosis, but that after chemother-
apy is associated with prognosis. However, a larger study
may be needed to prove this finding, and the molecular
mechanisms are needed for further in vitro or in vivo
investigations.
Surprisingly, our study found the variable expression
of CMTM1_v17 in tumor tissues before and after NAC
for patients with NSCLC. The phenomenon can be
Table 7 Univariate analysis of clinicopathological factors for OS and DFS in patients received NAC (n = 78)
Variables OS DFS
HR(95% CI) P value HR(95% CI) P value
Age 0.7963(0.3753–1.689) 0.5528 0.6167(0.3178–1.197) 0.1531
Gender 0.5719(0.2129–1.536) 0.2678 0.3019(0.1163–0.7836) 0.0138
Smoking history 1.648(0.7097–3.827) 0.2452 2.134(0.976–4.663) 0.0575
Histology 0.4711(0.2217–1.001) 0.0503 0.351(0.1761–0.6996) 0.0029
Histologic grading 1.425(0.6849–2.964) 0.3435 1.714(0.8874–3.312) 0.1086
Venous invasion 0.6148(0.2552–1.482) 0.2784 0.7369(0.3251–1.670) 0.4645
Pathological stage 0.3958(0.1894–0.8274) 0.0137 0.3351(0.1717–0.6540) 0.0014
CMTM1_v17 expression 0.3095(0.1442–0.6643) 0.0026 0.3655(0.1871–0.7142) 0.0032
P value was calculated using a two-sided log-rank test
NAC neoadjuvant chemotherapy, HR hazard ratio (log-rank), CI confidence interval.
Bold values are significant (P < 0.05)
Table 8 Multivariable analysis of OS and DFS in patients received NAC (n = 78)
Variable OS DFS
HR 95%CI P value HR 95%CI P value
CMTM1_v17
High vs low 3.642 1.594–8.324 0.002 3.094 1.507–6.350 0.002
Pathological stage
III vs I/II 2.862 1.316–6.224 0.008 2.704 1.315–5.560 0.007
Gender
Male vs female 1.026 0.399–2.636 0.958
Histology
Adenocarcinoma vs non-Adenocarcinoma 2.038 0.879–4.727 0.097
P value was calculated using a two-sided log-rank test
OS overall survival, DFS disease-free survival, HR hazard ratio (log-rank), CI confidence interval.
Bold values are significant (P < 0.05)
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explained that during chemotherapy, tumor cells will
redistribute and cells resisting to chemotherapy will
gradually expand at the expense of their relatively che-
mosensitive counterparts, resulting in difference of gene
expression before and after treatment. In addition, the
changes of inflammatory states and tumor microenviron-
ment regulated by inflammatory cytokines may further
influence tumor genome [28–30].
Conclusion
CMTM1_v17 expression is significantly associated with
chemotherapy resistance and poor prognosis of the early
stage NSCLC patients who have received NAC.
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